FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2408658112> ?p ?o ?g. }

• W2408658112 endingPage "83" @default.
• W2408658112 startingPage "179" @default.
• W2408658112 abstract "To evaluate the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis (TB) in those areas carrying out the 'TB control project'.TB cases involved in this study were from TB drug resistance surveillance in Heilongjiang province, Zhejiang province and Shenzhen city from 2004 to 2006. TB cases with rifampicin resistant were randomly divided into the treatment group (including fluoroquinolones anti-tuberculosis drugs group) and the control group (re-treatment regimen group). The treatment group was treated with 3RFT AM Ofx Pto PAS-INH/5RFT Ofx Pto PAS-INH while the control group was treated with 3 H3R3Z3E3S3/5 H3R3E3. Efficacy of short-term treatment was analyzed by per-protocol analysis (PP analysis) and intention-to-treat analysis (ITT analysis) while drug adverse reactions was also observed.(1) 154 patients with rifampicin resistant pulmonary tuberculosis were recruited among them, 25 (16.2%) were only resistant to rifampicin, 114 (74.0%) to MDR-TB and 15 (9.8%) to others (resistant R+S, resistant R+E and resistant R+E+S). 114 TB cases completed the full course of treatment,with 71 in the treatment group and 43 in the control group. (2) Sputum negative conversion rate of the treatment group and the control group were 78.9% and 65.1% (chi2CMH = 4.558, P = 0.011) respectively, by per-protocol analysis. Sputum negative conversion rate of the treatment group and the control group were 65.9% and 40.6% (chi2CMH = 0.272, P = 0.001) respectively, by intention-to-treat analysis. The sputum negative conversion rate of the treatment group was higher than in the control group when treating rifampicin resistant pulmonary tuberculosis and MDR-TB patients. (3) Three patients withdrew in each of the two groups because of adverse effects to the drugs. Rates of adverse reaction to drugs appeared to be 23.9% (17/71) and 18.6% (8/43) in the treatment and in the control groups, with no statistically significant difference between the two groups.The efficacy of treatment including fluoroquinolones anti-tuberculosis drugs group seemed better than the re-treatment regimen group in treating patients with rifampicin resistant pulmonary tuberculosis and those MDR-TB patients." @default.
• W2408658112 created "2016-06-24" @default.
• W2408658112 creator A5020446309 @default.
• W2408658112 creator A5026863467 @default.
• W2408658112 creator A5038346134 @default.
• W2408658112 creator A5042105305 @default.
• W2408658112 creator A5051099827 @default.
• W2408658112 creator A5054565575 @default.
• W2408658112 creator A5058190721 @default.
• W2408658112 creator A5062688045 @default.
• W2408658112 creator A5073783404 @default.
• W2408658112 creator A5078812431 @default.
• W2408658112 creator A5083318124 @default.
• W2408658112 date "2009-02-01" @default.
• W2408658112 modified "2023-09-27" @default.
• W2408658112 title "[Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis]." @default.
• W2408658112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19565883" @default.
• W2408658112 hasPublicationYear "2009" @default.
• W2408658112 type Work @default.
• W2408658112 sameAs 2408658112 @default.
• W2408658112 citedByCount "0" @default.
• W2408658112 crossrefType "journal-article" @default.
• W2408658112 hasAuthorship W2408658112A5020446309 @default.
• W2408658112 hasAuthorship W2408658112A5026863467 @default.
• W2408658112 hasAuthorship W2408658112A5038346134 @default.
• W2408658112 hasAuthorship W2408658112A5042105305 @default.
• W2408658112 hasAuthorship W2408658112A5051099827 @default.
• W2408658112 hasAuthorship W2408658112A5054565575 @default.
• W2408658112 hasAuthorship W2408658112A5058190721 @default.
• W2408658112 hasAuthorship W2408658112A5062688045 @default.
• W2408658112 hasAuthorship W2408658112A5073783404 @default.
• W2408658112 hasAuthorship W2408658112A5078812431 @default.
• W2408658112 hasAuthorship W2408658112A5083318124 @default.
• W2408658112 hasConcept C114851261 @default.
• W2408658112 hasConcept C126322002 @default.
• W2408658112 hasConcept C141071460 @default.
• W2408658112 hasConcept C142724271 @default.
• W2408658112 hasConcept C197934379 @default.
• W2408658112 hasConcept C2776301714 @default.
• W2408658112 hasConcept C2777025531 @default.
• W2408658112 hasConcept C2777107064 @default.
• W2408658112 hasConcept C2777768864 @default.
• W2408658112 hasConcept C2777975735 @default.
• W2408658112 hasConcept C2778607973 @default.
• W2408658112 hasConcept C2779912665 @default.
• W2408658112 hasConcept C2781069245 @default.
• W2408658112 hasConcept C2781413609 @default.
• W2408658112 hasConcept C71924100 @default.
• W2408658112 hasConcept C86803240 @default.
• W2408658112 hasConcept C89423630 @default.
• W2408658112 hasConceptScore W2408658112C114851261 @default.
• W2408658112 hasConceptScore W2408658112C126322002 @default.
• W2408658112 hasConceptScore W2408658112C141071460 @default.
• W2408658112 hasConceptScore W2408658112C142724271 @default.
• W2408658112 hasConceptScore W2408658112C197934379 @default.
• W2408658112 hasConceptScore W2408658112C2776301714 @default.
• W2408658112 hasConceptScore W2408658112C2777025531 @default.
• W2408658112 hasConceptScore W2408658112C2777107064 @default.
• W2408658112 hasConceptScore W2408658112C2777768864 @default.
• W2408658112 hasConceptScore W2408658112C2777975735 @default.
• W2408658112 hasConceptScore W2408658112C2778607973 @default.
• W2408658112 hasConceptScore W2408658112C2779912665 @default.
• W2408658112 hasConceptScore W2408658112C2781069245 @default.
• W2408658112 hasConceptScore W2408658112C2781413609 @default.
• W2408658112 hasConceptScore W2408658112C71924100 @default.
• W2408658112 hasConceptScore W2408658112C86803240 @default.
• W2408658112 hasConceptScore W2408658112C89423630 @default.
• W2408658112 hasIssue "2" @default.
• W2408658112 hasLocation W24086581121 @default.
• W2408658112 hasOpenAccess W2408658112 @default.
• W2408658112 hasPrimaryLocation W24086581121 @default.
• W2408658112 hasRelatedWork W1971853437 @default.
• W2408658112 hasRelatedWork W2013013057 @default.
• W2408658112 hasRelatedWork W2096259520 @default.
• W2408658112 hasRelatedWork W238453737 @default.
• W2408658112 hasRelatedWork W2408658112 @default.
• W2408658112 hasRelatedWork W2763250436 @default.
• W2408658112 hasRelatedWork W2807591323 @default.
• W2408658112 hasRelatedWork W2895817599 @default.
• W2408658112 hasRelatedWork W2906875615 @default.
• W2408658112 hasRelatedWork W2940729901 @default.
• W2408658112 hasVolume "30" @default.
• W2408658112 isParatext "false" @default.
• W2408658112 isRetracted "false" @default.
• W2408658112 magId "2408658112" @default.
• W2408658112 workType "article" @default.